CannabisNewsBreaks Archive - Page 212 of 217

ThursdayNov 02, 2017 12:44 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Acquisition of 100% Ownership Interest in Poviva Tea, LLC

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has acquired 100 percent ownership interest in its majority owned subsidiary, Poviva Tea, LLC. Lexaria previously owned 51 percent interest in Poviva Tea. “This acquisition strengthens Lexaria's intellectual property positioning and we reaffirm our commitment to the ViPova Tea product lines,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria thanks the founders of Poviva Tea, LLC for their assistance and vision in this transaction.” Per the update, compensation related…

WednesdayNov 01, 2017 10:10 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Receives Extensive Patent Allowance from USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, announced late yesterday that it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) related to the use of its innovative DehydraTECH™ technology as a delivery platform for the full list of active pharmacological ingredients requested, including all cannabinoids, fat-soluble vitamins, nonsteroidal anti-inflammatory pain medications (“NSAIDs”) and nicotine. The company expects formal patent issuance within three to four months, with provided protections extending through 2035 or later. “This wide-ranging patent allowance from the USPTO exceeds our expectations,” Chris Bunka, chief executive…

WednesdayOct 25, 2017 11:25 am

CannabisNewsBreaks – FinCanna Capital Corp. and Astar Minerals Ltd. (TSX.V: TAR) Announce Profit Sharing Agreement with Cultivation Technologies, Inc.

FinCanna Capital Corp., a royalty company for licensed medical cannabis, and Astar Minerals Ltd. (TSX.V: TAR) this morning announced that FinCanna will share 50 percent of the profits from Cultivation Technologies’ (“CTI”) interim medical cannabis extraction facility operating in Coachella, California. The new arrangement, which commenced on October 1, 2017, is expected to provide FinCanna with a source of monthly revenue before the construction of CTI’s Coachella campus is completed as planned. As noted in a news release issued on September 12, 2017, this interim medical cannabis extraction facility on the Coachella premises was established in accordance with CTI’s Conditional…

TuesdayOct 24, 2017 9:41 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Highlights Positive Pre-Clinical Data Related to Biosynthesis Platform

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced results from a study co-sponsored by InMed and the University of British Columbia. Notably, this study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens. “Importantly, this study offers further validation of InMed's capabilities in moving the science of cannabinoid pharmaceuticals forward,” Eric A. Adams, president and CEO of InMed, stated in the news release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned…

TuesdayOct 17, 2017 10:02 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on INM-405 Development

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced preclinical results in the development of INM-405 for the treatment of pain. Notably, results from the company’s studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects. InMed suggests that this lack of side effects may position cannabinoid-based compounds as more desirable treatment options than existing systemic pain-relief administration. News of these findings follows the company’s recent filing of a provisional patent application in the United States…

TuesdayOct 17, 2017 9:32 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the…

ThursdayOct 12, 2017 9:30 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive…

WednesdayOct 11, 2017 2:35 pm

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Sharpens Focus on Potentially Game-Changing Sustained Release Cannabinoid Formulation

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) recently entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release cannabinoid formulation. The agreement grants Emblem the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer—but not import or export—the product, which will be sold under the Emblem brand. An article discussing this reads: “For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are…

WednesdayOct 11, 2017 2:34 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scales Up in Preparation for Canada’s Impending 2018 Recreational Cannabis Legalization

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was one of the first companies to obtain a cannabis production license in Canada, and it continues going strong among the country’s limited number of licensed growers—only 62 to date. The company’s high-tech indoor growing environment—with every facet of the growing, curing and harvesting process controlled and monitored by computer—yields a high-quality product that is clean, steady and repeatable—something the company can effectively leverage should recreational cannabis legalization go through in 2018. An article discussing this reads: “Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology,…

TuesdayOct 10, 2017 9:51 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Addition of Dr. Mauro Maccarrone to Scientific Advisory Board

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the addition of Dr. Mauro Maccarrone to its scientific advisory board. Maccarrone is professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome. He also serves as director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. “InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs. One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

CannabisNewsBreaks